SoftBank fully exited Circle Internet Group in Q1 2026. Here is what investors need to know about the stablecoin giant's fundamentals.
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...
Barchart Research What to Expect from NMRA Earnings NMRA Generated May 8, 2026 Current Price $1.8300 EPS Estimate $$-0.25 Consensus Rating Moderate Buy Average Move 7.45% Neumora's Pipeline Credibility...
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation...
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that...
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of...
Barchart Research What to Expect from NMRA Earnings NMRA Generated March 27, 2026 Current Price $2.33 EPS Estimate $-0.34 Consensus Rating Moderate Buy Average Move 5.71% Neumora Therapeutics Has Been...
Barchart Research What to Expect from NMRA Earnings NMRA Generated March 27, 2026 Current Price $2.33 EPS Estimate $-0.34 Consensus Rating Moderate Buy Average Move 5.71% Neumora Therapeutics Has Been...
Barchart Research What to Expect from NMRA Earnings NMRA Generated March 27, 2026 Current Price $2.33 EPS Estimate $-0.34 Consensus Rating Moderate Buy Average Move 5.71% Neumora Therapeutics Has Been...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”)...